McKesson (NYSE:MCK) Updates FY25 Earnings Guidance

McKesson (NYSE:MCK) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of $31.75-32.55 for the period, compared to the consensus earnings per share estimate of $31.74.

McKesson Price Performance

Shares of MCK traded up $3.19 on Wednesday, hitting $617.51. The company’s stock had a trading volume of 840,415 shares, compared to its average volume of 705,391. The company has a 50 day moving average price of $591.09 and a 200 day moving average price of $549.29. McKesson has a fifty-two week low of $404.72 and a fifty-two week high of $637.51. The company has a market capitalization of $80.24 billion, a PE ratio of 27.59, a PEG ratio of 1.46 and a beta of 0.45.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $6.18 EPS for the quarter, missing analysts’ consensus estimates of $6.34 by ($0.16). McKesson had a negative return on equity of 245.88% and a net margin of 0.97%. The company had revenue of $76.36 billion for the quarter, compared to the consensus estimate of $79.32 billion. During the same period in the prior year, the company earned $7.19 EPS. The firm’s revenue was up 10.8% compared to the same quarter last year. On average, equities analysts forecast that McKesson will post 31.68 EPS for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Monday, September 2nd will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend is Friday, August 30th. This is a positive change from McKesson’s previous quarterly dividend of $0.62. McKesson’s dividend payout ratio is 11.08%.

Wall Street Analyst Weigh In

Several brokerages have commented on MCK. StockNews.com upgraded shares of McKesson from a buy rating to a strong-buy rating in a research report on Tuesday, July 23rd. Morgan Stanley raised their target price on McKesson from $522.00 to $548.00 and gave the stock an overweight rating in a report on Monday, April 15th. Wells Fargo & Company upped their price target on McKesson from $502.00 to $551.00 and gave the company an equal weight rating in a research note on Thursday, May 9th. Barclays boosted their price objective on shares of McKesson from $571.00 to $596.00 and gave the company an overweight rating in a report on Wednesday, May 8th. Finally, TD Cowen lifted their price target on shares of McKesson from $563.00 to $652.00 and gave the stock a buy rating in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $599.33.

Insider Transactions at McKesson

In other McKesson news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $574.41, for a total value of $2,155,760.73. Following the sale, the chief executive officer now owns 89,845 shares of the company’s stock, valued at approximately $51,607,866.45. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other McKesson news, CFO Britt J. Vitalone sold 12,752 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $558.09, for a total value of $7,116,763.68. Following the completion of the transaction, the chief financial officer now owns 14,028 shares of the company’s stock, valued at approximately $7,828,886.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Brian S. Tyler sold 3,753 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $574.41, for a total value of $2,155,760.73. Following the completion of the transaction, the chief executive officer now directly owns 89,845 shares of the company’s stock, valued at approximately $51,607,866.45. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,320 shares of company stock valued at $19,041,332. Company insiders own 0.11% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.